Chief, Division of Arthritis and Rheumatic Diseases Oregon Health & Science University Oregon Health & Science University Portland, Oregon
Virtually any portion of the eye can be a target of the immune or inflammatory response. While topical or local therapy is sometimes sufficient, systemic therapy is preferable in some instances. Uveitis, scleritis, dry eye, orbital inflammatory disease and giant cell arteritis are examples of ocular inflammation or diseases with ocular effects. Therapeutic approaches to these diseases with an emphasis on recent therapeutics will be discussed including adalimumab for uveitis, rituximab for scleritis, teprotumumab for thyroid eye disease, and tocilizumab for giant cell arteritis.